Clinical trials: Protease Inhibitor
HIV Infections
Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients
The purpose of this study is to see if the multidrug combination of zidovudine (ZDV), lamivudine (3TC), 1592U89 (abacavir [ABC]), and 141W94 (amprenavir [APV]) is a safe and effective treatment for HIV-infected patients and if…
- Trial name
- NCT00006617
- Testing
- Abacavir sulfate, Amprenavir, Lamivudine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine
The purpose of this study is to compare the effectiveness of treatment with BMS-232632 to that of efavirenz (EFV) when both are used with zidovudine (ZDV) and lamivudine (3TC).
- Trial name
- NCT00013897
- Testing
- Atazanavir, Lamivudine/Zidovudine, Efavirenz
- Where
- 99 sites in United States, Austria and 22 more
- Sponsor
- Bristol-Myers Squibb
HIV Infection
Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa
Multicenter, randomized, superiority trial to evaluate efficacy of a mono or bi-therapy of protease inhibitors with or without lamivudine over a period of 96 weeks. The primary outcome will be the failure rate at 96 weeks.
- Trial name
- MOBIDIP (NCT01905059)
- Testing
- monoPI - boosted lopinavir or boosted darunavir, bi therapy - (boosted lopinavir or boosted darunavir) + lamivudine
- Where
- 5 sites in Burkina Faso, Cameroon and 1 more
- Volunteers
- 265 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Type 2 Diabetes Mellitus
Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus
The purpose of this study is to confirm the mechanism of reduced response to DPP-4 inhibitor in some patients with type 2 diabetes and evaluate appropriate patients to treat with DPP-4 inhibitor
- Trial name
- NCT01449747
- Testing
- Sitagliptin
- Where
- 2 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- The Catholic University of Korea
Acquired Immunodeficiency Syndrome
PI Vs. NNRTI Based Therapy for HIV Advanced Disease
Ritonavir boosted protease inhibitor based therapy will have equivalent antiviral efficacy over 48 weeks compared to NNRTI based therapy in patients who are antiretroviral therapy naïve and initiate therapy with CD4 counts ≤…
- Trial name
- NCT00162643
- Testing
- zidovudine+lamivudine+lopinavir/ritonavir, zidovudine + lamivudine + efavirenz
- Where
- 5 sites in Mexico
- Volunteers
- 300 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran